tbuckley/cabot-search huggingface dataset:
ZOSTER ENCEPHALOMYELITIS
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.
Authors: Julie R. Park, Susan G. Kreissman, Wendy B. London, Arlene Naranjo, Susan Lerner Cohn, Michael D. Hogarty, Sheena Cretella Tenney, Daphne Haas-Kogan, Peter John Shaw, James Duncan Geiger, John J Doski, Sandra Wooton Gorges, Geetika Khanna, Stephan D. Voss, John M. Maris, Stephan A. Grupp, Lisa Diller
Journal: Journal of Clinical Oncology (2016)

LBA3 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Sunday, June 5, 2016, and in the Annual Meeting Proceedings online supplement to the June 20, 2016, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.
HIV-infected surgeons and dentists. Looking back and looking forward
Authors: B. Mishu
Journal: JAMA (1993)

The recent reports of transmission of the human immunodeficiency virus (HIV) from a Florida dentist with the acquired immunodeficiency syndrome (AIDS) to five patients in his practice has heightened concern about the possibility of transmission of HIV from infected health care workers.<sup>1-4</sup>However, a thorough epidemiologic investigation revealed no deviations from standard infection control practices in the dentist's office that could explain these transmissions.<sup>4</sup>Thus, the specific mechanism by which HIV was transmitted from the dentist to his patients remains unresolved. See also pp 1795, 1802, and 1807. Although this event frequently has been characterized as an aberration because no other cases of HIV transmission from health care workers to patients have been reported, in fact, it rather closely resembles several previously reported features of hepatitis B virus (HBV) transmission in surgical or dental settings.<sup>5-8</sup>Typical dentist- or surgeon-to-patient transmission of HBV is likely to produce clusters
PSYCHO-ANALYSIS
Authors: J. Glover
Journal: BMJ (1917)

1T917of the service than in any other, and that the order for a ';movo on" as often as not com-es from a higher source than the officer commanding unit to which the officer lhas juLst beeni posted.Again, au officer whlo hias filled nearlyevery post from regiment to homne hospital has in many cases hiad this privilege, not as the result of beinig a " square peg," bnt through the more honoturable circutmstances-of sicklness and wounds inivaliding him home in thle first place, and on recovery being once more ready for (lisposal.There are many yonna medical officers in otr h-ospitals whlo, h-aving become interested in some particuilar line, are apparently muclh keener on self-impr-ovement and in compiling notes for, publicationi, thtan in thinking of getting a "mi:ove on..A period as regimental mnedical officer or with troops in tle-fire zone wotuld be a spiendid discipline for them, and impress upon them the wonders of the otler side of thje service, and incidentally pave thle way for the local talent of the medical men resident in civil practice in the neighbourhood to be tUsed to thle best advantage.---Iam, etc., January 14tih.
Mesenteric Panniculitis
Authors: Laurence A. Grossman
Journal: JAMA (1963)

Isolated involvement of the adipose tissue of the mesentery of the small intestine sometimes occurs without similar pathological change in the subcutaneous tissue or other abdominal organs. Four patients with this syndrome are described. Pain was a prominent symptom. An abdominal mass was palpable in two of four patients. Diagnosis is difficult without abdominal exploration. The condition is benign, and spontaneous recovery is likely. Therefore, it is important to make a correct diagnosis and to limit the surgical procedure to obtaining biopsy material.
Radiosynoviorthesis (Radiation Synovectomy)
Authors: Gynter Mödder
Journal: Clinical Nuclear Medicine (2020)

Radiosynoviorthesis (RSO) is a proven important instrument for local treatment of chronic inflammatory joint diseases in the context of medical and orthopaedic efforts. The term radiosynoviorthesis was created by Delbarre et al. [1], meaning the restoration (orthesis) of the synovium by means of radionuclides. By local administration of radioactive agents, an attempt is made to influence the synovial process favourably as an alternative to surgical synovectomy. In the Anglo-American literature the term "radiosynovectomy" or "radiation synovectomy" came into use.
SHOCK
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Cover
Authors: Paul Quartararo
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Body Compositional Changes in Response to Testosterone-Reply
Authors: Gilbert B. Forbes
Journal: JAMA (1992)

<h3>In Reply.</h3> —We wish to respond to the points raised by Coodley et al in their comments on our article.<sup>1</sup>We did not state or imply that anabolic steroids are a safe, reasonable approach for normal healthy men to increase muscle mass. The normal volunteers reported in<i>JAMA</i>were monitored closely. As reported earlier,<sup>2</sup>there were no changes in serum cholesterol or serum triglyceride levels, or liver function tests. Serum creatinine and creatine kinase levels, and hematocrit rose significantly while plasma follicle-stimulating hormone, luteinizing hormone, and thyroxine levels fell. Subjects were interviewed and evaluated monthly for side effects. Acne and weight gain were the only changes. Not reported previously were the facts that blood pressure, mood, and muscle strength as measured with a hand dynamometer did not change significantly and consistently in this short-term study. The normal men were studied concurrently with adult ambulatory men with myotonic dystrophy
Regulation of human Gc (vitamin d?binding) protein levels: Hormonal and cytokine control of gene expression in vitro*1
Authors: C GUHA
Journal: Hepatology (1995)

Studies were performed in Hep3B hepatocytes to better elucidate the mechanisms regulating circulating levels of human group—specific component (Gc). We measured changes in Gc messenger RNA (mRNA) synthesis and levels of secreted protein resulting from treatment of hepatocytes with cytokines and hormones known to influence synthesis of other proteins of hepatic origin. We particularly focused on compounds known to be prototypic stimulants during the acute phase response. Interleukin-6 (IL-6) and dexamethasone were shown to increase Gc mRNA approximately twofold while transforming growth factor beta (TGFβ) decreased Gc mRNA in a dose-dependent fashion by up to fivefold. The effects on secreted Gc protein levels were similar. These results indicate that Gc protein appears to be regulated differently than the other members of this gene family, albumin and alpha-fetoprotein (AFP), which are negative acute phase reactants. In addition, these contrasting effects on Gc synthesis of IL-6 and dexamethasone and of TGFβ suggest that high basal levels of Gc synthesis may be maintained during the acute phase response.
Choosing the right medicine— AMA's Lonnie Bristow, MD, talks reform
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Oral decontamination and ventilator-associated pneumonia
Authors: G. V. Poole
Journal: JAMA (1991)

<h3>To the Editor.</h3> —Two articles<sup>1,2</sup>and a related editorial<sup>3</sup>in a recent issue of<i>JAMA</i>discussed the cost of medical care in Canada and the cost impact of the number of physicians produced by our training systems. It is most surprising that in these three articles, neither the differences between Canada and the United States in respect to the medical care needs of indigent patients or the needs within the United States for expanding the care of underserved groups were considered. Clearly, the employment levels of the two countries are major factors in the structure of medical care systems and should not be overlooked in these types of evaluations.
PDTM-37. NEW THERAPEUTIC APPROACH FOR BRAINSTEM GLIOMA: INTRANASAL DELIVERY OF NANOLIPOSOMAL SN-38
Authors: Xingyao He, Nundia Louis, Peng Zhang, Irina Balyasnikova, Craig Horbinski, Stewart Goldman, Rintaro Hashizume
Journal: Neuro-Oncology (2017)

Children with diffuse intrinsic pontine gliomas (DIPGs) die within 2 years after initial diagnosis. The infiltrative nature and anatomic location of DIPGs in an eloquent area of the brain preclude surgical resection, and the blood-brain barrier (BBB) reduces the availability of systemically administered agents. In order to improve outcomes for patients with DIPG, new drug delivery approach circumventing the BBB are greatly needed. Intranasal delivery (IND) is a practical, noninvasive method to deliver therapeutic agents into the brain along with the olfactory and trigeminal nerves pathway. With the advantages of reducing systemic side effects and convenient self-administration for patients, IND is an alternative to systemic (intravenous) and/ or direct invasive (intraparechymal) drug delivery. Two human DIPG cell lines were treated with hydrophobic fluorophore (DiI)–labeled nanoparticle liposomes containing CPT-11 (nanoliposomal CPT-11) and SN-38. Cell viability was determined by MTS assay and intracellular localization was imaged by confocal microscopy. For in vivo study, mice bearing human brainstem gliomas were randomly assigned to 3 groups: 1. empty nanoliposomes, 2. nanoliposomal CPT-11, 3. nanoliposomal SN-38, administrating by IND for 3 weeks. In vivo distribution was determined by DiI–labeled nanoliposomal SN-38 into the tumor bearing mice. Tumor growth and response to therapy were quantitatively measured by bioluminescence imaging, and efficacy was assessed by survival analysis. DiI-fluorescence were detected at 30 minutes and peaked at 24 hours following treatment with DiI nanoliposomal SN-38. Nanoliposomal SN-38 induced dose dependent inhibition of the growth of DIPG cells, that is greater inhibition than nanoliposomal CPT-11. IND of nanoliposomal SN-38 showed significant reduction of the growth rate in compared to IND of empty nanoliposome. Results from animal survival will be reported at the meeting.
Poetry and Medicine
Authors: Andrew D. Firlik
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Experts at Buenos Aires conference predict pandemic of tobacco deaths
Authors: A. A. Skolnick
Journal: JAMA (1992)

THE WORLD is facing a pandemic of tobacco-related diseases that is likely to kill one fifth of all who now live in industrialized countries, if current smoking trends continue. People in the third world will face a similar fate if they continue to adopt the smoking habits of wealthier nations. If current smoking trends persist over the next 30 years, 7 million residents of developing countries will die every year of smoking-related diseases. Thus, smoking will become the world's leading cause of premature death. These were some of the dire predictions reported at the recent Eighth World Conference on Tobacco OR Health in Buenos Aires, Argentina, by Richard Peto, professor of medical statistics at Oxford University's Imperial Cancer Research Center, England, and Alan D. Lopez, PhD, an epidemiologist for the Tobacco or Health Program of the World Health Organization (WHO) in Geneva, Switzerland. Their gloomy forecast is based on extrapolations
Lipoprotein(a)
Authors: Daniel J. Rader
Journal: JAMA (1992)

<h3>SELECTED CASE</h3> A 42-YEAR-OLD man was referred because of premature coronary artery disease (CAD). He had been healthy until 3 months earlier, when he sustained a non—Q wave myocardial infarction. Cardiac catheterization revealed severe triple-vessel coronary disease, and he underwent coronary artery bypass grafting. He was not a smoker and had no history of diabetes mellitus or hypertension. Family history was remarkable for a father who died of an acute myocardial infarction at the age of 54 years. Three weeks after surgery, a random serum cholesterol level was 5.38 mmol/L. Physical examination of the patient at the National Institutes of Health revealed no corneal arcus, normal liver and spleen size, and no evidence of palmar, tuberoeruptive, or tendon xanthomas. Laboratory values included a normal fasting blood glucose, normal serum urea nitrogen, and normal serum tests of liver and thyroid function. Fasting plasma lipid and lipoprotein values included the following: triglycerides,
Reply:
Authors: Massimo Pinzani, Umberto Arena, Francesco Vizzutti
Journal: Hepatology (2008)

We are very pleased about the interest and the debate elicited by our article "Acute viral hepatitis increases liver stiffness values measured by transient elastography"1 and we read with attention Ze-Zhou Song's letter to the editor. First of all, we must say that we are very sorry that Dr. Song had been concerned about some aspects of our manuscript, likely due to an insufficient understanding of the study purpose and design. Just to reassure Dr. Song, we are pleased to provide the following comments. As clearly stated in the introduction of our paper, the aim of the study was to provide further evidence about the contribution of necroinflammation to liver stiffness measured by transient elastography. Patients with acute viral hepatitis without a previous history of liver disease were specifically selected in order to elucidate the role of necroinflammation. In other words, acute viral hepatitis was employed as a model of extensive necroinflammation in the absence of a fibrotic background. As our fellow citizen Niccolò Machiavelli would say, "The ends justify the means". The conclusions of our study do not reflect at all Dr. Song's concerns about the utility of this noninvasive methodology for assessing the fibrotic evolution of chronic liver disease. We are actually convinced that this is an excellent tool, especially when confounding factors and particularly those related to disease activity are carefully considered. The time frame of our study comprised a period from the peak increase of aminotransferase levels to their normalization. Established clinical guidelines do not indicate liver biopsy in a setting of uncomplicated acute viral hepatitis. In addition, it was beyond the aim of the study to provide information on the clinical follow-up of the patients included in the study. Regardless of this, up to now, all 18 patients show signs of complete remission without clinical evidence indicating chronic liver disease. Concerning the influence of gender, body mass index, and metabolic syndrome on liver stiffness values measured in a general population, we would like to reassure Dr. Song that we were very much aware of this influence when the study was designed, as reflected by the strict exclusion criteria detailed in the Patients and Methods section. Finally, the impact of different viral agents on the extent of acute liver damage evaluated by an increase in aminotransferase levels in a limited cohort of 18 patients was really beyond the aim and the relevance of the information provided by this article. Nevertheless, it appears (see table 2 in the article) that patients with acute hepatitis B had higher peak alanine aminotransferase and aspartate aminotransferase levels than did patients with acute hepatitis A and C. Massimo Pinzani M.D., Ph.D.*, Umberto Arena M.D.*, Francesco Vizzutti M.D., Ph.D.*, * Department of Internal Medicine, Università degli Studi di Firenze, Florence, Italy.
CD73-Generated Extracellular Adenosine Creates Microenvironmental Conditions Favoring Growth and Survival of Chronic Lymphocytic Leukemia Cells
Authors: Sara Serra, Alberto Horenstein, Tiziana Vaisitti, Davide Brusa, Davide Rossi, Luca Laurenti, Giovanni D'Arena, Marta Coscia, Claudio Tripodo, Giorgio Inghirami, Simon Robson, Gianluca Gaidano, Fabio Malavasi, Silvia Deaglio
Journal: Blood (2011)
Apoptotic effects of heparin on lymphoblasts, neutrophils, and mononuclear cells: Results of a preliminary in vitro study
Authors: Erol Erduran, Yavuz Tekelioğlu, Yusuf Gedik, Alişan Yıldıran
Journal: American Journal of Hematology (1999)

In this study the apoptotic effects of heparin on lymphoblasts, neutrophils, and mononuclear cells were evaluated by flow cytometry for detection of sub-G1 peak, in vitro. Ten children with acute lymphoblastic leukemia (ALL) at diagnosis (Group I), six children with ALL at relapse (Group II), and 10 healthy children (controls) were included in this study. Lymphoblasts in ALL patients, and neutrophils and mononuclear cells in controls, were incubated in increasing heparin concentrations (0, 5, 10, 20 U/ml). Flow cytometric analyses were performed at 0, 1, and 2 hours of incubation in heparin for determination of the apoptotic effects of heparin. In Group I apoptosis was detected in all different levels of heparin concentration except 0 U/ml at 0, 1, and 2 hours. The apoptotic effects of heparin on blast cells peaked at the first hour in 5-, 10-, and 20-U/ml heparin concentrations (p < 0.0001). In Group II similar findings were observed only at zero hour and apoptosis was higher than those in Group I except in 5-U/ml heparin concentration (p < 0.001). Apoptosis was found to increase with heparin levels in both groups (p < 0.02). In the control group, apoptosis was detected only at the 20-U/ml heparin concentration and only at the first and second hours. Lymphoblasts are more sensitive to apoptotic effects of heparin than either neutrophils and mononuclear cells (p < 0.004). It can be suggested that low-dose heparin may cause significant apoptosis of lymphoblasts while inducing no apoptosis on neutrophils and mononuclear cells. The findings of this preliminary study indicate that further and more comprehensive research on the apoptotic effect of heparin on lymphoblasts should be done. Am. J. Hematol. 61:90–93, 1999. © 1999 Wiley-Liss, Inc.